The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of ad...
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
About this item
Full title
Author / Creator
Rini, Brian I. , Battle, Dena , Figlin, Robert A. , George, Daniel J. , Hammers, Hans , Hutson, Tom , Jonasch, Eric , Joseph, Richard W. , McDermott, David F. , Motzer, Robert J. , Pal, Sumanta K. , Pantuck, Allan J. , Quinn, David I. , Seery, Virginia , Voss, Martin H. , Wood, Christopher G. , Wood, Laura S. and Atkins, Michael B.
Publisher
England: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy in 2015 for aRCC after treatment with a VE...
Alternative Titles
Full title
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_eee5402a5743458ab14e581acfdc6861
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_eee5402a5743458ab14e581acfdc6861
Other Identifiers
ISSN
2051-1426
E-ISSN
2051-1426
DOI
10.1186/s40425-019-0813-8
